. 2016 Sep 1;38(5):1311–1317. doi: 10.1007/s11096-016-0371-9

Table 3.

Self-reported indications for antidepressant use and presence of depressive symptoms

	N	Median CES-D score Median (IQR)	Presence of depressive symptoms^d N (%)
Non–use	10,797	2.0 (0.0–7.0)	877 (8.1)
Reported indication for use ^a
Depression	436	11.0 (3.0–20.8)^b	161 (36.9)^b
Single indications except depression	410	8.0 (3.0–15.0)^b,c	96 (23.4)^b,c
Anxiety	59	5.0 (2.0–13.0)^b,c	10 (16.9)^b,c
Stress	105	9.5 (3.0–16.5)^b	27 (24.7)^b,c
Sleep disorders	33	7.0 (3.0–15.5)^b	8 (24.2)^b
Headache/migraine	8	1.0 (0.0–14.3)	2 (25.0)
Pain	48	5.0 (1.0–13.8)^b,c	9 (18.8)^b,c
Other	44	6.5 (2.3–13.0)^b,c	7 (15.9)^c
Unknown	113	9.0 (4.5–16.9)^b	33 (29.2)^b
Multiple indications	42	12.5 (4.5–20.0)^b	18 (42.9)^b

Complete caseset analysis. St John’s wort was not taken into account as antidepressant and excluded from the non-use group. N does not correspond with total N in Table 2: CES-D data was missing for 26 antidepressant users, and participants with multiple indications or antidepressants were categorized in a separate group (‘multiple’), and were only taken into account once

CES-DCenter for Epidemiological Studies Depression Score, IQR interquartile range

^aReported indications for antidepressant use represent disorders and related symptoms. See Table 1

^bSignificantly different from non-use (p < 0.05)

^cSignificantly different from the indication ‘depression’ (p < 0.05)

^dPresence of depressive symptoms is based on a Center for Epidemiological Studies Depression Score of 16 or higher